Imperial College London

DrLucaMagnani

Faculty of MedicineDepartment of Surgery & Cancer

Principal Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 2808l.magnani CV

 
 
//

Location

 

140ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Patten:2018:10.1038/s41591-018-0091-x,
author = {Patten, DK and Corleone, G and Gyrffy, B and Perone, Y and Slaven, N and Barozzi, I and Erds, E and Saiakhova, A and Goddard, K and Vingiani, A and Shousha, S and Pongor, LS and Hadjiminas, DJ and Schiavon, G and Barry, P and Palmieri, C and Coombes, RC and Scacheri, P and Pruneri, G and Magnani, L},
doi = {10.1038/s41591-018-0091-x},
journal = {Nature Medicine},
pages = {1469--1480},
title = {Enhancers mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer},
url = {http://dx.doi.org/10.1038/s41591-018-0091-x},
volume = {24},
year = {2018}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - The degree of intrinsic and interpatient phenotypic heterogeneity and its role in tumor evolution is poorly understood. Phenotypic drifts can be transmitted via inheritable transcriptional programs. Cell-type specific transcription is maintained through the activation of epigenetically defined regulatory regions including promoters and enhancers. Here we have annotated the epigenome of 47 primary and metastatic estrogen-receptor (ERα)-positive breast cancer clinical specimens and inferred phenotypic heterogeneity from the regulatory landscape, identifying key regulatory elements commonly shared across patients. Shared regions contain a unique set of regulatory information including the motif for transcription factor YY1. We identify YY1 as a critical determinant of ERα transcriptional activity promoting tumor growth in most luminal patients. YY1 also contributes to the expression of genes mediating resistance to endocrine treatment. Finally, we used H3K27ac levels at active enhancer elements as a surrogate of intra-tumor phenotypic heterogeneity to track the expansion and contraction of phenotypic subpopulations throughout breast cancer progression. By tracking the clonality of SLC9A3R1-positive cells, a bona fide YY1-ERα-regulated gene, we show that endocrine therapies select for phenotypic clones under-represented at diagnosis. Collectively, our data show that epigenetic mechanisms significantly contribute to phenotypic heterogeneity and evolution in systemically treated breast cancer patients.
AU - Patten,DK
AU - Corleone,G
AU - Gyrffy,B
AU - Perone,Y
AU - Slaven,N
AU - Barozzi,I
AU - Erds,E
AU - Saiakhova,A
AU - Goddard,K
AU - Vingiani,A
AU - Shousha,S
AU - Pongor,LS
AU - Hadjiminas,DJ
AU - Schiavon,G
AU - Barry,P
AU - Palmieri,C
AU - Coombes,RC
AU - Scacheri,P
AU - Pruneri,G
AU - Magnani,L
DO - 10.1038/s41591-018-0091-x
EP - 1480
PY - 2018///
SN - 1078-8956
SP - 1469
TI - Enhancers mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer
T2 - Nature Medicine
UR - http://dx.doi.org/10.1038/s41591-018-0091-x
UR - http://hdl.handle.net/10044/1/60145
VL - 24
ER -